proteintech nox4 (Proteintech)
Proteintech is a verified supplier 
96
Structured Review
Proteintech
proteintech nox4
Proteintech Nox4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 449 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteintech+nox4/NOX4+Antibody/pm41500376-170-54-54
Average 96 stars, based on 449 article reviews
Proteintech Nox4, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 449 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/proteintech+nox4/NOX4+Antibody/pm41500376-170-54-54
Average 96 stars, based on 449 article reviews
proteintech nox4 - by Bioz Stars,
2026-10
96/100 stars
Images
Related Articles
Transfection:Article Title: Set7 regulates ferroptosis in pulmonary arterial hypertension endothelial cells through the DPP4/NOX4 axis mediated by H3K4me1 modification. Article Snippet: Objective: Dipeptidyl peptidase-4 (DPP4)-targeted therapy is widely employed in the therapy of pulmonary diseases, but the role of its H3K4me1 modification in pulmonary arterial hypertension (PAH) disease remains unknown.. This study aims to investigate the function of histone methyltransferase SET domain containing 7 (Set7)-mediated monomethylation of histone 3 lysine 4 (H3K4me1) modification of DPP4 in PAH, with the goal of providing new insights for the broader application of DPP4-targeted therapies.. Methods: The PAH mouse model was constructed and intervened with overexpression (oe) or knockdown (sh) of DPP4, sh-Set7, oe-NADPH oxidase 4 (NOX4) or sh-Set7 + erastin. Plasmid Preparation:Article Title: Set7 regulates ferroptosis in pulmonary arterial hypertension endothelial cells through the DPP4/NOX4 axis mediated by H3K4me1 modification. Article Snippet: Objective: Dipeptidyl peptidase-4 (DPP4)-targeted therapy is widely employed in the therapy of pulmonary diseases, but the role of its H3K4me1 modification in pulmonary arterial hypertension (PAH) disease remains unknown.. This study aims to investigate the function of histone methyltransferase SET domain containing 7 (Set7)-mediated monomethylation of histone 3 lysine 4 (H3K4me1) modification of DPP4 in PAH, with the goal of providing new insights for the broader application of DPP4-targeted therapies.. Methods: The PAH mouse model was constructed and intervened with overexpression (oe) or knockdown (sh) of DPP4, sh-Set7, oe-NADPH oxidase 4 (NOX4) or sh-Set7 + erastin. |
